Drug Guidance for Subsidy 08/02/2023 Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus NRThe Ministry of Health’s Drug Advisory Committee has not recommended palivizumab for inclusi... See all × 08/02/2023 Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus NRThe Ministry of Health’s Drug Advisory Committee has not recommended palivizumab for inclusion on the MOH List of Subsidised Drugs for prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease, because it does not represent a cost-effective use of healthcare resources at the price proposed by the company.
General Availability in Public Healthcare Institution Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration Synagis Injection, Solution 100 mg/mL KK Women's and Children's Hospital National University Hospital Singapore General Hospital
INTRAMUSCULAR Select a brand starting with the letter: S SYNAGIS SOLUTION FOR INJECTION 100MG/ML [SIN15112P]